RICHMOND, Va. - Altria Group , Inc. (NYSE: NYSE:MO), the $89 billion tobacco giant, today announced its financial results for the fourth quarter of 2024 and provided its full-year earnings guidance for 2025.

Shares of Altria Group dipped 0.3% to $52.51. The cigarette manufacturer reported earnings of $1.29 a share on revenue of $5.1 billion, in line with FactSet consensus estimates. F

A government website shows the Trump administration has withdrawn the Food and Drug Administration’s proposed ban of menthol-flavored

Altria Group Inc (MO) reports robust earnings growth and shareholder returns, while navigating the complexities of the illicit e-vapor market.

Is there any ban on menthol cigarettes in US? The Food and Drug Administration had in April 2022 proposed to ban the sale of menthol cigarettes and flavored cigars, but its implementation was delayed several times by the Biden administration, as per a report.

Q4 2024 Earnings Call Transcript January 30, 2025 9:00 AM ETCompany ParticipantsMac Livingston - Vice President of

The Trump administrations removed FDA's plan to ban menthol cigarettes. The Biden administration did not finalize the rule amid opposition.

Altria exited that stake in 2023. Altria Group Inc.'s stock fell Thursday after the tobacco giant said it continues to face the challenge of counterfeit products in the rapidly growing vape market. But the company narrowly beat Wall Street's fourth-quarter earnings projections.

The Biden administration never finalized a ban on menthol cigarettes, and the Trump administration withdrew the proposal. The American Lung Association is criticizing Biden's inaction.

The American Lung Association gave Kentucky mostly failing grades when it comes to preventing tobacco use in a new report.

Zyn is manufactured by Swedish Match, which Philip Morris International acquired in a $16 billion deal in 2022. That year, Zyn shipped 238 million cans in the U.S. Philip Morris International forecasts that the total more than doubled in 2024. Zyn's growth comes as the company looks to transition more to smokeless products.

Despite the seemingly restrictive nature of the FDA's proposed ruling, I remain highly optimistic about the resilience and adaptability